E-viri
Odprti dostop
-
Thompson, Mark G; Burgess, Jefferey L; Naleway, Allison L; Tyner, Harmony L; Yoon, Sarang K; Meece, Jennifer; Olsho, Lauren E W; Caban-Martinez, Alberto J; Fowlkes, Ashley; Lutrick, Karen; Kuntz, Jennifer L; Dunnigan, Kayan; Odean, Marilyn J; Hegmann, Kurt T; Stefanski, Elisha; Edwards, Laura J; Schaefer-Solle, Natasha; Grant, Lauren; Ellingson, Katherine; Groom, Holly C; Zunie, Tnelda; Thiese, Matthew S; Ivacic, Lynn; Wesley, Meredith G; Lamberte, Julie Mayo; Sun, Xiaoxiao; Smith, Michael E; Phillips, Andrew L; Groover, Kimberly D; Yoo, Young M; Gerald, Joe; Brown, Rachel T; Herring, Meghan K; Joseph, Gregory; Beitel, Shawn; Morrill, Tyler C; Mak, Josephine; Rivers, Patrick; Harris, Katherine M; Hunt, Danielle R; Arvay, Melissa L; Kutty, Preeta; Fry, Alicia M; Gaglani, Manjusha
MMWR. Morbidity and mortality weekly report, 04/2021, Letnik: 70, Številka: 13Journal Article, Newsletter
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. locations during December 14, 2020-March 13, 2021, CDC routinely tested for SARS-CoV-2 infections every week regardless of symptom status and at the onset of symptoms consistent with COVID-19-associated illness. Among 3,950 participants with no previous laboratory documentation of SARS-CoV-2 infection, 2,479 (62.8%) received both recommended mRNA doses and 477 (12.1%) received only one dose of mRNA vaccine. Among unvaccinated participants, 1.38 SARS-CoV-2 infections were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) per 1,000 person-days. In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.